Anupam Rasayan annual revenue grew 65%, but margins shrank
Annual sales soared on recent acquisitions, yet higher costs squeezed EBITDA margins and caused a quarterly profit drop.
What's new
- Annual revenue climbed 65% YoY in FY26.
- EBITDA margins thinned to 23% from 28% the prior year.
- Q4 net profit dropped 11% compared to the same quarter last year.
Why this matters
Revenue growth is not protecting the bottom line. With EBITDA margins falling 5 percentage points, expansion costs are eating into returns. This is the central test for the company's new acquisitions.
What we're watching
- Whether margins recover in the coming fiscal year.
- Integration costs for the Jayhawk acquisition.
- Revenue contribution from the Bliss GVS Pharma deal.
The full read
Anupam Rasayan reported a busy FY26. Annual revenue jumped 65% after the company finalized the Jayhawk acquisition and signed a contract with Bliss GVS Pharma.
But growth has a cost. EBITDA margins thinned to 23% from 28% a year ago. Profits suffered. Q4 net profit dropped 11% YoY as those higher costs hit the bottom line. The business is expanding, yet it lacks the efficiency needed to keep earnings steady. Investors are waiting to see if these margins will recover as the company settles into its new structure. That is the next test.
Questions answered
- How did the bottom line perform in the latest quarter?
- Net profit fell 11% YoY during Q4. This follows a full-year trend of tighter margins.
- How much did EBITDA margins change in FY26?
- Margins declined to 23%, down from 28% in the previous year. This indicates rising input or operational costs.
- What drove the company's revenue growth?
- The 65% annual revenue jump came from strategic additions like the Jayhawk acquisition and the Bliss GVS Pharma contract.
- Is the margin decline a one-time event?
- The filing shows a steady decline throughout the year. The open question is whether management can improve efficiency in the next quarter.